Better drugs through AI? Insitro CEO on what machine learning can teach Big Pharma

AP Health Writer

WASHINGTON (AP) — Artificial intelligence is changing the way industries do business. But executives in the pharmaceutical industry are still waiting to see whether AI can tackle their biggest challenge: finding faster, cheaper ways to develop new drugs. Despite billions poured into research and development, new medicines still typically take a decade or more to develop. Insitro is part of a growing field of AI companies promising to accelerate drug discovery by using machine learning to analyze huge datasets that could lead to new medicines.